Nanoparticulate strategies for the delivery of miRNA mimics and inhibitors in anticancer therapy and its potential utility in oral submucous fibrosis

MicroRNAs (miRNAs) are naturally occurring noncoding RNAs with multiple functionalities. They are dysregulated in several conditions and can serve as disease biomarkers, therapeutic targets and therapeutic agents. Translation of miRNA therapeutics to the clinic poses several challenges related to the safe and effective delivery of these agents to the site of action. Nanoparticulate carriers hold promise in this area by enhancing targeting efficiency and reducing off-target effects. This paper reviews recent advances in the delivery strategies of miRNAs in anticancer therapy, with a focus on lipid-based, polymeric, inorganic platforms, cell membrane-derived vesicles and bacterial minicells. Additionally, this review explores the potentiality of miRNAs in the treatment of oral submucous fibrosis, a potentially premalignant condition of the oral cavity with no definitive treatment to date.

Download Full-text

Immunohistochemical Analysis of Myofibroblasts Using α- SMA in Oral Submucous Fibrosis Turning into Malignancy- A Case Report and Review

Journal of Pharmaceutical Research International ◽

10.9734/jpri/2021/v33i52a33575 ◽

2021 ◽

pp. 192-198

Author(s):

Swapan Kumar Purkait ◽

. Abhinandan ◽

Nimisha Priya ◽

Sriyanshi Singh ◽

Sneha Singh

Keyword(s):

Case Report ◽

Immunohistochemical Study ◽

Oral Submucous Fibrosis ◽

Mouth Opening ◽

Immunohistochemical Analysis ◽

Invasive Front ◽

Premalignant Condition ◽

Submucous Fibrosis ◽

Very High ◽

Premalignant Conditions

Oral submucous fibrosis is a premalignant condition, characterized by fibrosis in oral mucosa causing stiffness of mucosa and leading to reduced mouth opening. The malignant transformation of oral submucous fibrosis is very high among the rest of the premalignant conditions. Chronic chewing of arecanut causes production of myofibroblasts. These myofibroblasts plays an important role in neoangiogenesis as well as disintegration of the basement membrane at the tumor invasive front leading to carcinoma. Here, we are doing an Immunohistochemical study using alpha SMA for proper microscopic visulizations of myofibroblastic activity in an OSF patient, encompassing the pathogenesis and malignant potentiality of the disease.

Download Full-text

Nasolabial Flap in the Management of Oral Submucous Fibrosis

Journal of Mahatma Gandhi University of Medical Sciences and Technology ◽

10.5005/jp-journals-10057-0007 ◽

2016 ◽

Vol 1 (1) ◽

pp. 27-29

Author(s):

Vaishali Jamdade ◽

Amit LNU

Keyword(s):

Surgical Treatment ◽

Physical Therapy ◽

Oral Submucous Fibrosis ◽

Mouth Opening ◽

Oral Carcinoma ◽

Treatment Modalities ◽

Nasolabial Flap ◽

Mahatma Gandhi ◽

Premalignant Condition ◽

Submucous Fibrosis

ABSTRACT Oral submucous fibrosis (OSMF) is a premalignant condition associated with restricted mouth opening. Oral submucous fibrosis is poorly understood and unsatisfactorily treated disease. Serious complication is the risk of development of oral carcinoma. Different treatment modalities like medical, surgical, physical therapy or combination are used to improve the condition of the patient. Surgical treatment is usually indicated in late and irreversible stage of the disease. Successful use of nasolabial flap in the management of OSMF is presented. How to cite this article Jamdade V, Sharma S, Chitlangia P, Amit. Nasolabial Flap in the Management of Oral Submucous Fibrosis. J Mahatma Gandhi Univ Med Sci Tech 2016;1(1):27-29.

Download Full-text

Oral submucous fibrosis: a premalignant condition in a 14-year-old Indian girl

BMJ Case Reports ◽

10.1136/bcr-2013-200786 ◽

2013 ◽

Vol 2013 (dec12 1) ◽

pp. bcr2013200786-bcr2013200786 ◽

Cited By ~ 2

Author(s):

A. Deshpande ◽

S. Kiran ◽

S. Dhillon ◽

R. Mallikarjuna

Keyword(s):

Oral Submucous Fibrosis ◽

Indian Girl ◽

Premalignant Condition ◽

Submucous Fibrosis

Download Full-text

Oral Submucous Fibrosis - A Review

Journal of Evolution of Medical and Dental Sciences ◽

10.14260/jemds/2021/544 ◽

2021 ◽

Vol 10 (32) ◽

pp. 2665-2671

Author(s):

Falguni Patel ◽

Shreyas N. Shah ◽

Christina James

Keyword(s):

Oral Cavity ◽

Precancerous Lesions ◽

Oral Submucous Fibrosis ◽

Classification Systems ◽

Oral Disease ◽

Areca Nut ◽

Functional Aspects ◽

Premalignant Condition ◽

Submucous Fibrosis ◽

Upper Third

A common oral disease named as oral submucous fibrosis (OSMF) has the tendency to usually affect many areas of the oral cavity as well as involving the area of pharynx. The characteristic feature of oral submucous fibrosis is the fibrosis in submucosal area which involves maximum part of oral cavity leading to advanced lock jaw as a result of rigidity in cheeks, pharynx, lips and upper third part of the oesophageal canal progressing to dysphagia. It has been reported that OSMF occurs mainly in persons who are habituated to chew areca nut or products containing areca nut along with other ingredients. In recent years with the introduction of commercially available Gutka and other areca nut products, the incidence of OSMF is increasing especially in the younger generations. OSMF is irreversible and persists even after cessation of chewing habit and the severity increases along with the duration of habit. In 2007, the categorization of oral submucous fibrosis was done as a premalignant condition by WHO and it has higher chances of malignant transformation. Early diagnosis and application of proper treatment modality is mandatory to reduce morbidity and mortality rate. There are many classification systems that have been proposed in literature for oral submucous fibrosis, among which many are based on clinical features, some of them on functional aspects and others are based on histopathological aspects. Here is an attempt to enlighten the facts and recent updates of clinical, functional, histopathological features as well as pathogenesis and management of oral submucous fibrosis. The complete knowledge of oral submucous fibrosis is a useful to the clinicians as well as academicians and researchers for timely detection and proper management of the disease. KEY WORDS Oral Submucous Fibrosis, Precancerous Lesions, Precancerous Conditions, Sclerosing Stomatitis

Download Full-text

Hypoxia Inducible Factor-1α (HIF-1α): A Biomarker for Detection of Malignant Transformation in Oral Submucous Fibrosis

Pakistan Journal of Medicine and Dentistry ◽

10.36283/pjmd10-3/014 ◽

2021 ◽

Keyword(s):

Malignant Transformation ◽

Oral Submucous Fibrosis ◽

Hypoxia Inducible Factor ◽

Asian Population ◽

Hypoxia Inducible Factor 1Α ◽

Cell Stability ◽

Premalignant Condition ◽

Submucous Fibrosis ◽

And Function ◽

Upper Third

Oral submucous fibrosis (OSMF) is a premalignant condition, which involves the oral cavity as well as pharynx and upper third of the esophagus. It is a predominant disease of South and South-East Asian population. OSMF has the highest rate of malignant transformation among the other oral premalignant disorders (OPMD) that is 7-30% with a prevalence of about 0.03% to 6.42%. OSMF is described by extensive fibrosis of submucosa and reduced vascularity, which results in compromised blood supply guiding to hypoxia of tissue. This tissue hypoxia brings about the transcription of a set of genes associated with angiogenesis, breakdown of iron/glucose, cell division and cell stability. Hypoxia Inducible Factor-1α (HIF-1α) is the main biomarker intervening in this reaction. The alteration of cells to hypoxia emerges to be mediated through hypoxia inducible factor, which is said to be linked with malignant transformation of epithelium. Research-based studies covered on the probable mechanism of HIF-1α were explored using PubMed and Google Scholar. In this review, we analyzed over 40 articles from the years 2004-2021, which were published regarding the structure and function of HIF-1α, and its association with OSMF. Research articles in which HIF-1α is used separately or in combination with other biomarkers in oral submucous fibrosis have been selected. Keywords: Biomarker; Oral Submucous Fibrosis; Esophagus; Hypoxia.

Download Full-text

Prevalence and management of oral submucous fibrosis and its implications on prosthodontic treatment: A retrospective study

International Journal of Research in Pharmaceutical Sciences ◽

10.26452/ijrps.v11ispl3.3498 ◽

2020 ◽

Vol 11 (SPL3) ◽

pp. 1702-1709

Author(s):

Vatika Agarwal ◽

Subhabrata Maiti

Keyword(s):

Oral Submucous Fibrosis ◽

Epidemiological Data ◽

Treatment Modalities ◽

Effective Management ◽

Asian Countries ◽

Prosthetic Rehabilitation ◽

Non Invasive ◽

Premalignant Condition ◽

Submucous Fibrosis ◽

Spss Software

Oral submucous fibrosis is a chronic, premalignant condition that is prevalent in Asian countries like India, Pakistan and Srilanka. Oral cancer accounts for around 30% of the cancer cases in India. It is important to understand the prevalence of the disease for its effective management. The aim of the study was to understand the prevalence of the condition and the popularity of various treatment modalities used in its management, along with the prevalence of OSMF patients requiring prosthetic rehabilitation. Case sheets of around 23,000 patients were reviewed from March 2019 to June 2020 out of which 100 patients were affected by oral submucous fibrosis. To eliminate bias, all patients affected by the disease were included in the study. Epidemiological data of the patient along with their ongoing treatment, was collected and tabulated in MS Excel sheet. The data was then analyzed using IBM SPSS software version 23: The prevalence of OSMF in males was 92% while in females, it was 8%. The age group of 31-40 years was found to be most commonly affected, and pan chewing was observed to be the most common abusive habit amongst OSMF patients. The most common treatment modality used was non-invasive methods within which antioxidant therapy was the most popularly used modality. The increasing prevalence of OSMF amongst the younger population is a matter of great concern. The present study shows the prevalence of OSMF in males, especially in the young and middle-aged population. Thus it is important to increase awareness amongst the youth regarding the condition and to increase awareness amongst the dentists regarding the various treatment modalities to effectively prevent and clinically manage such conditions.

Download Full-text

Tanshinones in management of oral submucous fibrosis and oral squamous cell carcinoma

Oncobiology and Targets ◽

10.18639/onbt.2017.04.456966 ◽

2017 ◽

Vol 04 ◽

pp. 1 ◽

Cited By ~ 1

Author(s):

Vagish Kumar L Shanbhag ◽

◽

Keyword(s):

Squamous Cell Carcinoma ◽

Oral Squamous Cell Carcinoma ◽

Cell Carcinoma ◽

Squamous Cell ◽

Oral Submucous Fibrosis ◽

The Novel ◽

Asian Countries ◽

Premalignant Condition ◽

Submucous Fibrosis ◽

Current Article

Oral submucous fibrosis is a premalignant condition predominantly occurring in Southeast Asian countries. Oral squamous cell carcinoma is the most common type of oral cancer. The current article highlights the promising benefits of the novel agent tanshinones (TSNs) in the management of oral submucous fibrosis and oral squamous cell carcinoma. The letter is written with the aim to promote more research on TSNs in the management of oral submucous fibrosis and oral squamous cell carcinoma.

Download Full-text

Small Molecule “Silmitasertib” Repurposed as Inhibitor of Transforming Growth Factor Beta 1 for the Development of Therapeutics for Oral Submucous Fibrosis

BioMed Research International ◽

10.1155/2021/6631848 ◽

2021 ◽

Vol 2021 ◽

pp. 1-8

Author(s):

Nezar Boreak

Keyword(s):

Growth Factor ◽

Transforming Growth Factor Beta ◽

Transforming Growth Factor ◽

Oral Submucous Fibrosis ◽

Normal Tissues ◽

Premalignant Condition ◽

Submucous Fibrosis ◽

Transformation Potential ◽

Growth Factor Beta ◽

Tgf Β1

Oral submucous fibrosis (OSMF) is considered a premalignant condition characterized by aggressive fibrosis of the submucosal tissues of the oral cavity reflecting its malignant transformation potential. Activation of transforming growth factor beta (TGF-β) signaling has been reported to lead increased collagen production and fibrosis. Recently, significant upregulation of TGF-β1 has been reported in OSMF as compared to normal tissues. Therefore, inhibition of the TGF-β1 may pave for the development of therapeutics of OSMF. Based on the structure-assisted drug designing, we found “silmitasertib” as potent inhibitor of TGF-β1. We suggest that this molecule can be validated and implemented for the treatment of OSMF.

Download Full-text

A Short Review on OSMF : Oral Submucous fibrosis

Journal of Current Medical Research and Opinion ◽

10.15520/jcmro.v3i09.337 ◽

2020 ◽

Vol 3 (09) ◽

Author(s):

Dr. Vishal Thakur ◽

Dr. Supriya Jassal ◽

Dr. Atul Kumar ◽

Dr. Sadaf J Malik ◽

Dr. Pallavi Sharma ◽

...

Keyword(s):

Drug Therapy ◽

Oral Cancer ◽

Clinical Symptoms ◽

Oral Submucous Fibrosis ◽

Short Review ◽

Tobacco Consumption ◽

Band Formation ◽

Premalignant Condition ◽

Submucous Fibrosis ◽

Fibrotic Band

Oral submucous fibrosis (OSMF) is a premalignant condition caused by betel chewing. OSMF is a premalignant condition that can lead to oral cancer. A risk that is further increased by concomitant tobacco consumption. OSMF is a diagnosis based on clinical symptoms and confirmation by histopathology. Major constituents of betel quid are arecoline from betel nuts and copper, which are responsible for fibroblast dysfunction and fibrotic band formation. Drug therapy include antifibrotic, anti-inflammatory, and antioxidants, homemade remedies including turmeric and tulsi . Prevention is most important in case of OSMF , because severe cases of OSMF are irreversible.

Download Full-text

Oral submucous fibrosis: a study of qualitative and analytical treatment using intralesional injections: placental extract versus combination of steroid with hyaluronidase

International Journal of Otorhinolaryngology and Head and Neck Surgery ◽

10.18203/issn.2454-5929.ijohns20202786 ◽

2020 ◽

Vol 6 (7) ◽

pp. 1320

Author(s):

Meena Vishwanath Kale ◽

Ninad Subhash Gaikwad

Keyword(s):

Symptomatic Relief ◽

Oral Submucous Fibrosis ◽

Mouth Opening ◽

Definitive Treatment ◽

Unknown Etiology ◽

Intralesional Injection ◽

Group A ◽

Submucous Fibrosis ◽

Group B ◽

Placental Extract

Background: One of the premalignant conditions in oropharynx is oral submucous fibrosis (OSMF). It is a chronic debilitating condition of unknown etiology leading to fibrosis of mucosa affecting the oropharynx, esophagus and thus causes decreased mouth opening and dysphagia respectively. The disease is of multifactorial etiology with addictions, nutritional, micro elements and antioxidants deficiencies. In India males are more affected than females, due to their stress related excessive, irresponsible chewing habits. The available management is for symptomatic relief and at present there is no definitive treatment is available.Methods: We have studied 60 cases diagnosed with OSMF with mild to moderate restricted mouth opening. Most of patients were between 17 to 55 years of age selected by randomized clinical trial. Its management was divided into 2 groups where group A was treated with a combined intralesional regimen of injection triamcinolone 40mg and hyaluronidase 1500 IU, while group B was treated with injection of 2ml placental extract. Each group has given a single dose intralesional injection per week for six weeks. Results: It was a comparative study of improvement in effectiveness on mouth opening and reduction in burning sensation of oral cavity seen in group A regimen than group B. Those having persistent trismus, needed surgery.Conclusions: No effective treatment available but along with intralesional injection can give symptomatic relief. In addition, cessation of habits, antioxidants oral hygiene helps in improvement of OSMF.

Download Full-text